Scynexis Inc (SCYX) Stock Analysis

Scynexis Inc (SCYX) is a publicly traded company in the HEALTHCARE sector. It trades at $5.10, carries a market capitalization of $56.01M. This page summarizes the public market data, fundamentals, and frequently asked questions for SCYX, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - DRUG MANUFACTURERS - SPECIALTY & GENERIC

Exchange: NASDAQ

Key Metrics

Market Sentiment

Scynexis Inc currently has a Neutral sentiment score of -0.12.

About Scynexis Inc

Scynexis Inc. is a biotechnology firm headquartered in Jersey City, New Jersey, specializing in innovative therapies for the treatment of invasive fungal infections, with a particular focus on serious yeast infections. The company’s lead product candidate, BREXAFEMME®, is the first oral therapeutic specifically indicated for the treatment of vulvovaginal candidiasis, representing a significant advancement in antifungal therapy. With a robust pipeline and a commitment to addressing unmet medic...

GNG Research Analysis

GNG Research scores Scynexis Inc (SCYX) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for SCYX.

Frequently Asked Questions

Does SCYX pay dividends?

Scynexis Inc (SCYX) does not currently pay a regular dividend.

What is SCYX's market cap?

Scynexis Inc (SCYX) has a market capitalization of $56.01M with a current stock price of $5.10.